Tag: Nalmefene

From June 2020 to June 2022, emergency medical services administered naloxone in over 744,000 incidents in the U.S. [1.7.1]. Understanding **what are the most common opioid antagonists** is crucial for addressing opioid overdose, use disorders, and side effects [1.4.3].

In May 2023, the U.S. Food and Drug Administration (FDA) approved nalmefene nasal spray (Opvee®), a new opioid reversal medication for emergency use. This marks a significant development in the fight against the opioid crisis, building on decades of experience with naloxone, the standard opiate reversal drug.